单硝酸异山梨酯联合沙库巴曲缬沙坦钠治疗慢性心力衰竭患者的临床效果分析

Analysis of the Clinical Application Effect of Isosorbide Mononitrate Combined with Sacubitril/Valsartan Sodium in the Treatment of Patients with Chronic Heart Failure

目的对单硝酸异山梨酯与沙库巴曲缬沙坦钠联合疗法在慢性心力衰竭患者的临床应用效果进行分析。方法便利选取2023年2月—2024年2月青海省海东市第二人民医院收治的86例慢性心力衰竭患者为研究对象,根据不同治疗方法分为两组,各43例,对照组采用沙库巴曲缬沙坦钠治疗,观察组在上述基础联用单硝酸异山梨酯治疗。对比两组患者的症状缓解时间、心功能、生活质量、激素水平与不良反应发生率。结果观察组呼吸困难、咳嗽咳痰、胸闷气短、乏力疲惫症状缓解时间均短于对照组,差异有统计学意义(P均<0.05)。观察组左心室射血分数高于对照组,左心室舒张末期内径、左心室后壁厚度小于对照组,差异有统计学意义(P均<0.05)。观察组的生活质量评分低于对照组,且激素水平低于对照组,差异有统计学意义(P均<0.05)。观察组的不良反应发生率为18.60%(8/43),略高于对照组的9.30%(4/43),但差异无统计学意义(χ²=1.550,P>0.05)。结论单硝酸异山梨酯与沙库巴曲缬沙坦钠联合治疗慢性心力衰竭患者具有较好的临床效果,能够缩短患者的症状缓解时间,改善心功能和激素水平,提高患者生活质量。

Objective To analyze the clinical application effect of the combined therapy of isosorbide mononitrate and sacubitril/valsartan sodium in patients with chronic heart failure.Methods 86 patients with chronic heart failure admitted to The Second People's Hospital of Haidong City in Qinghai Province from February 2023 to February 2024 were conveniently selected as the research objects.According to different treatment methods,they were divided into two groups,with 43 cases in each group.The control group was treated with sacubitril/valsartan sodium,and the observation group was treated with isosorbide mononitrate on the basis of the above.The symptom relief time,heart function,quality of life,hormone level and incidence of adverse reactions were compared between the two groups.Results The remission time of dyspnea,cough and expectoration,chest tightness and shortness of breath,fatigue and fatigue in the observation group was shorter than that in the control group,and the differences were statistically significant(all P<0.05).The left ventricular ejection fraction in the observation group was higher than that in the control group,and the left ventricular end diastolic diameter and left ventricular posterior wall thickness were smaller than those in the control group,the differences were statistically significant(all P<0.05).The quality of life score of the observation group was lower than that of the control group,and the hormone level was lower than that of the control group,the differences were statistically significant(both P<0.05).Although the incidence of adverse reactions in the observation group was 18.60%(8/43),slightly higher than 9.30%(4/43)in the control group,the difference was not statistically significant(χ²=1.550,P>0.05).Conclusion The combined treatment of isosorbide mononitrate and sacubitril/valsartan sodium has a good clinical effect in patients with chronic heart failure,which can effectively shorten the symptom relief time of patients,improve heart function and hormone levels,and improve the quality of life of patients.